The debate over the optimal mode of revascularisation for unprotected left main (ULM) coronary artery disease intensified with the advent of drug-eluting stents (DES). Professional society guidelines addressing ULM disease have been revised at an increasing frequency, 1,2 the significance of randomised comparisons has been variously interpreted, and observational comparisons have become a veritable cottage industry. Making matters even more complicated, the debate is often depicted in simplified, polarised terms in the lay press and at national meetings. Not surprisingly, patients and clinicians alike are often left confused. The intention of this review is to place the 'debate' in context and highlight a few of the crucial issues in generalising the evidence base for those who manage ULM disease in clinical practice.
The Evolution of the 'Gold Standard'Coronary artery bypass graft (CABG) surgery had been unchallenged as the standard of care for patients with ULM disease for decades. Before addressing the evidence for percutaneous coronary intervention (PCI) as an alternative, it is important to briefly consider the quality of that supporting CABG as an alternative to medical therapy for ULM disease. Only two of the seminal randomised trials comparing CABG with medical therapy included patients with left main disease. Observational data gave support to this finding, 6 and the paradigm of CABG to prolong longevity for left main disease remained essentially unchallenged for three decades.There are important caveats concerning these early randomised trials that warrant emphasis. First, only 150 patients in total were randomised, quite a small number by contemporary standards.Second, they represent a pooled subgroup analysis and should be viewed with the attendant limitations of such analyses.7 Third, and perhaps most importantly, both surgery and medical therapy have evolved tremendously over the ensuing decades. CABG now routinely includes the use of mammary conduits, and surgical mortality has improved considerably -in the registry component of the CoronaryArtery Surgery Study (CASS) it was over 4 % for patients with left main disease, a rate that most would consider unacceptable today.Conversely, 'medical therapy' at the time of these trials consisted of digitalis, beta-blockers and nitrates. Not even aspirin was routinely administered. Suffice it to say, the evidence base for the longevity benefits of CABG over medical therapy for treating left main coronary disease is neither large nor current.
Observational Trials of Coronary Artery Bypass Graft for Unprotected Left Main DiseaseAlthough randomised clinical trials (RCTs) are considered the most robust assessment of efficacy, they have important limitations. Patients in RCTs tend to be younger, more often male and have fewer co-morbid conditions. 8 Generalising results from these trials must therefore be done with caution. For example, the vast majority of patients in the aforementioned Veterans Affairs and European studies were under 60 years of age and most...